The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

Condition(s) targeted: Diabetic Foot Ulcer

Intervention: gentamicin-collagen sponge and levofloxacin (Drug); Levofloxacin only (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Innocoll Technologies

Official(s) and/or principal investigator(s):
David Prior, Study Director, Affiliation: Innocoll Technologies

Overall contact:
Lisa Hemsen, Phone: 860-610-5530, Ext: 5530, Email: skinulcers@premier-research.com

The purpose of this study is to determine whether the gentamicin-collagen sponge (Collatamp G topical) when combined with standard daily wound care and an oral antibiotic (levofloxacin) is safe and effective in treating moderately infected skin ulcers compared to treatment only with standard daily wound care and an oral antibiotic (levofloxacin).

Official title: A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The percent of patients with a clinical outcome of "clinical cure" in each treatment group at Visit 3

Secondary outcome:

The percent of patients with a positive clinical response at each time point

The percent of patients with a "clinical cure"

The percent of patients with pathogen eradication

Absolute change in total wound surface area in each treatment group

Time to clinical cure

Time to positive clinical response

Time on parenteral antimicrobial therapy

Visual Analog Scale (VAS) for pain assessment

Lipsky wound score

Treatment emergent adverse events

Detailed description: Infected skin ulcers with diabetes can be very debilitating because they are difficult to heal. Diabetic ulcers are responsible for frequent health care visits, and are a major predictor of amputation. Diabetic ulcers can be caused by a patient's inability to sense pain or warmth as well as peripheral vascular disease, which causes diminished blood flow to the foot. Early aggressive treatment is necessary to treat infection and ultimately prevent the need for amputation.

Gentamicin is an antibiotic that is effective in treating certain kinds of infection. Collagen is a protein that is found in all mammals. The gentamicin-collagen sponge is a thin flat sponge made out of collagen that comes from cow tendons and containing gentamicin. When applied to an open ulcer, the collagen breaks down and the gentamicin is released into the ulcer, but very little is absorbed into the blood stream. The high levels of gentamicin in the open infected ulcer may help treat the infection.

In this study, all subjects will be given the necessary supplies and taught how to take care their foot ulcer. All subjects will also receive oral an antibiotic (levofloxacin). Additionally, subjects who are randomly assigned to receive the gentamicin-collagen sponge will place a gentamicin-collagen sponge on their ulcer during daily wound care.

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Is a man or woman aged ≥ 18 and ≤ 80 years.

- Has diabetes mellitus, according to the American Diabetes Association criteria.

- Has a single infected skin ulcer below the knee, defined as "moderate" by the

Infectious Disease Society of America (IDSA) Guidelines for whom, in the Investigator's opinion, intravenous (IV) or oral antimicrobial therapy is appropriate

- Has had an x ray of the infected area within the 2 days immediately preceding or at

Visit 1 (Baseline/Randomization) to document the presence or absence of osteomyelitis. Patients with osteomyelitis must receive appropriate surgical intervention to remove all necrotic and infected bone and otherwise meet enrollment criteria before being enrolled in the study.

- Meets certain minimal laboratory criteria

- Has an ankle brachial index (ABI) > or = 0. 7 and ≤ 1. 3. (Note: Patients with ABI

< 0. 7 or > 1. 3 may be included if they have either a transcutaneous oxygen pressure or a toe pressure > or = 40 mm Hg on limb with ulcer.)

- If female, is nonpregnant (negative pregnancy test results at the

Baseline/Randomization Visit) and nonlactating.

- If female, is either not of childbearing potential (defined as postmenopausal for ≥

1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing a medically acceptable methods of birth control and agrees to continue with the regimen throughout the study

- Willing to return to the study facility for the Final Study Visit.

- Must be able to fluently speak and understand English and be able to provide

meaningful written informed consent for the study.

Exclusion Criteria:

- Has a known history of hypersensitivity to gentamicin (or other systemic

aminoglycosides) or levofloxacin or drugs in the same class, or any of the test article or reference product components.

- Has a known hypersensitivity to bovine collagen.

- Has any uncontrolled illnesses that, in the opinion of the Investigator, would

interfere with interpreting the results of the study.

- Has a target ulcer with a wound size > 10 × 10 cm.

- Has gangrenous tissue of the affected limb that cannot be removed with a single

debridement.

- Has wound known to contain isolates resistant to levofloxacin.

- Has a wound associated with prosthetic material or device.

- Received any topical or systemic antimicrobial therapy within the 2 weeks prior to

study entry (Visit 1 [Day 1]).

- If severely immunocompromised, may be excluded at the discretion of the Investigator.

- Has a history of alcohol or substance abuse in the past 12 months.

- Has serum creatinine > 3 mg/dL, is undergoing dialysis (renal or peritoneal) or has

a history of kidney transplant.

- Has a history of myasthenia gravis or other neurological condition where gentamicin

use is contraindicated as determined by the Investigator.

- Has a history of epilepsy

- Has a history of tendon disorders related to fluoroquinolone administration

Lisa Hemsen, Phone: 860-610-5530, Ext: 5530, Email: skinulcers@premier-research.com

Karr Foot Kare PA, Lakeland, Florida 33813, United States; Recruiting
Jeffrey C. Karr, DPM, Principal Investigator

Starting date: April 2008
Ending date: April 2009
Last updated: January 8, 2009